Vision Loss Clinical Trial
— ACTIVISOfficial title:
Evaluation of the Perception of Objects and Natural Scenes in People With Vision Loss (Loss of Central or Peripheral Vision)
Verified date | August 2016 |
Source | Lille Catholic University |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Observational |
The loss of central vision causes difficulty not only in reading but also in faces recognition, and in particular in the identification of facial expression, objects or spaces. These visual deficits have been mainly studied in relation with reading, which is the main complaint of these kind of patients. However, there are not enough data regarding perception of objects and spaces in this population. Then, the objectives are to study the visual-spatial abilities in individuals with vision loss, and altered cognitive processes, (2) to develop clinics tools for early detection and quantification of visual-spatial deficits and (3)to understand the capacities of normal peripheral vision in order to test the possibility of potential training for use of peripheral vision when central vision is impaired by an ophthalmic pathology.
Status | Completed |
Enrollment | 260 |
Est. completion date | March 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria cases: - Patients with eye disease causing loss of central or peripheral vision - French speakers - Age between 18 and 90 years old - Written consent - Health insurance Inclusion Criteria controls: - Sex and age matched controls (+/- 5 years) - French speakers - Normal visual examination with visual acuity of min 9/10 Exclusion Criteria: - Psychiatric disease or neurological pathologies - Communication difficulties (deafness / mutism) - Drug treatment altering concentration - Mental deterioration with MMS <24 - Alcoholism or addiction to drugs - Persons under guardianship |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lille Catholic University | University Hospital, Lille |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of performances in visual tests between different groups according to error rate | These behavioral studies include a series of short tests of 5 to 10 minutes each (not exceeding 60 minutes with breaks and instructions) in which photos of scenes or isolated objects will be presented in central or peripheral vision using a computer screen or a panoramic screen covering a 180° field. | at inclusion | No |
Primary | Comparison of performances in visual tests between different groups according to answer time | These behavioral studies include a series of short tests of 5 to 10 minutes each (not exceeding 60 minutes with breaks and instructions) in which photos of scenes or isolated objects will be presented in central or peripheral vision using a computer screen or a panoramic screen covering a 180° field. | at inclusion | No |
Secondary | Estimation of the score of visual acuity by the logMAR chart | at inclusion | No | |
Secondary | Measure of lesion size | at inclusion | No | |
Secondary | Pearson correlation coefficient to determine the correlation between the performance parameters during visual tests (error rate and answer time) and clinical parameters (visual acuity and lesion size) | These behavioral studies include a series of short tests of 5 to 10 minutes each (not exceeding 60 minutes with breaks and instructions) in which photos of scenes or isolated objects will be presented in central or peripheral vision using a computer screen or a panoramic screen covering a 180° field. | at inclusion | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01598818 -
First-Sight Refractive Error Correction in the Developing World
|
||
Completed |
NCT01838655 -
Nitisinone for Type 1B Oculocutaneous Albinism
|
Phase 1/Phase 2 |